Euformatics
Euformatics is a Finland-based bioinformatics company that builds software tools to interpret genomic sequence data, with a focus on delivering cancer-relevant variant interpretation from a single test for clinical and research users.
- Company typePrivate
- Founded2010
- HeadquartersEspoo, Finland
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Euformatics does
Euformatics is a Finland-based, privately held bioinformatics company founded in 2010 and headquartered in Espoo. The firm builds software tools that interpret genomic sequence data, with product positioning aimed at delivering cancer-relevant variant interpretation from a single test — implying a consolidated clinical reporting workflow aimed at clinical genetics and oncology reference workflows rather than a broad life-science research audience. The company operates as a small for-profit with 1-10 employees, consistent with a focused specialist vendor serving clinical laboratories, hospital genetics departments, or research consortia in Nordic and European markets.
The company's underlying technology stack centers on bioinformatics interpretation pipelines — variant calling, annotation, and clinical interpretation logic — though no detailed architectural disclosures (core engine, supported assays, validation status, or certifications such as IVDR/CE-IVD) are present in the available data. No app, SDK, MCP, or API documentation is recorded, suggesting the product is most likely delivered as a service, on-prem pipeline, or licensed analysis platform rather than a self-serve cloud product. Revenue mechanics are not disclosed; the absence of pricing details, customer logos, or named channels indicates a low-volume, high-touch commercial motion typical of a niche clinical bioinformatics vendor.
Euformatics' only documented external capital event is a ~$365K European Commission grant in July 2022, structured as non-dilutive public funding led by the Commission itself. No venture rounds, M&A, partnerships, executive appointments, product launches, or regulatory milestones are recorded in the source data. The combination of small headcount, single grant funding event, and absent commercial disclosures signals a firm that is either in early commercialization, sustained by public/grant funding, or operating in a low-volume services-plus-software hybrid mode.
Euformatics firmographics
Firmographics- Name
- Euformatics
- Website
- https://euformatics.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Euformatics is a Finland-based bioinformatics company that builds software tools to interpret genomic sequence data, with a focus on delivering cancer-relevant variant interpretation from a single test for clinical and research users.
- Ownership category
- akta.pro rank
Euformatics industry classification
Industry- Product category
- Clinical Bioinformatics Software
- NAICS
- Software Publishers (5132)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
- akta.pro secondary industries
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA)
Keywords
Where Euformatics is headquartered
LocationHeadquarters
- HQ city
- Espoo
- HQ country
- Finland
- HQ region
- Europe
Markets served
Euformatics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Euformatics product offering
Product offeringCore offering
Euformatics develops and supplies high-standard bioinformatics software tools used to interpret next-generation sequencing (NGS) data. Its offering emphasizes a single-test capability that surfaces all cancer-relevant clinical genomic findings, supporting clinical laboratories and diagnostic providers in standardized oncology sequence interpretation.
Differentiator
Problem solved
Functional benefit
Products and services
- Euformatics Cancer Bioinformatics Interpretation Tool Standardized bioinformatics software used by clinical laboratories and molecular diagnostic providers to interpret next-generation sequencing data and produce all cancer-relevant clinical genomic findings from a single test.
Companies that use Euformatics
Customer profileIdeal customer profiles1 record
Euformatics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Euformatics partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights2 records
Euformatics competitors and assessment
Company assessmentDirect peers
- BC Platforms: BC Platforms is a Finland-headquartered genomics data and analytics company providing interpretation software for clinical and research workflows, making it a near-twin peer for Euformatics in both geography and offering.
- Sophia Genetics: Sophia Genetics offers the SOPHiA DDM platform for clinical genomic and multi-omic data interpretation, directly overlapping with Euformatics' cancer-focused sequence interpretation tools and similar hospital lab buyers.
- Molecular Health: Molecular Health offers clinical decision support and genomic interpretation for oncology and rare disease, targeting the same hospital and reference lab buyers as Euformatics.
- GenomOncology: GenomOncology provides clinical genomics decision support specifically for molecular tumor boards and oncology interpretation, directly comparable to Euformatics' cancer-focused workflow.
- Congenica: Congenica delivers a clinical genomics interpretation platform (Congenica Insights) for rare disease and cancer, competing directly with Euformatics for molecular pathology and clinical lab customers.
- Velsera (formerly PierianDx): Velsera provides the Clinical Genomics Workspace for NGS interpretation and clinical reporting, serving hospital and reference labs with comparable cancer interpretation workflows to Euformatics.
- Fabric Genomics (renamed Genomic Answers): Fabric Genomics delivers AI-driven clinical NGS interpretation software for hereditary disease and oncology, directly comparable in product scope and customer base to Euformatics' interpretation tools.
Broad incumbents
- QIAGEN Digital Insights: QIAGEN's Digital Insights business (including QCI Interpret) offers clinical NGS interpretation as part of a broader sample-to-insight portfolio, competing with Euformatics for clinical interpretation workflows from a position of much greater scale and breadth.
- Roche (Navify): Roche's Navify digital health portfolio includes clinical decision support and oncology workflow tools that intersect with Euformatics' interpretation offerings as part of a broader diagnostics and pathology portfolio.
Emerging players
- BlueBee (Illumina): BlueBee, now part of Illumina, provides clinical genomics data processing and interpretation infrastructure for sequencing-based diagnostics, overlapping with Euformatics on interpretation software delivery models.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Euformatics social profiles
Digital presenceEuformatics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Euformatics leadership team
Management profileNumber of profiles
Euformatics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Euformatics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Euformatics
What does Euformatics do?
Euformatics develops and supplies high-standard bioinformatics software tools used to interpret next-generation sequencing (NGS) data. Its offering emphasizes a single-test capability that surfaces all cancer-relevant clinical genomic findings, supporting clinical laboratories and diagnostic providers in standardized oncology sequence interpretation.
When was Euformatics founded?
Euformatics was founded in 2010. It employs 1 to 10 people.
Where is Euformatics based?
Euformatics is headquartered in Espoo, Finland, in the Europe region.
Who are Euformatics's main competitors?
Direct peers on record are BC Platforms, Sophia Genetics, Molecular Health, GenomOncology, Congenica, Velsera (formerly PierianDx) and Fabric Genomics (renamed Genomic Answers). Broad incumbents are QIAGEN Digital Insights and Roche (Navify). BlueBee (Illumina) is listed as an emerging player.
Does Euformatics have an API?
No public API is recorded for Euformatics.
What industry is Euformatics in?
Euformatics's product category is Clinical Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 5132 and its SIC code is 8731.